



Afinitor ER+/HER2- Breast Cancer ATU – Wave 4

Presentation: July 30, 2013


Revised: August 8, 2013



When evaluating prescribing by line, ONCs use of Afinitor is highest in the 2nd and 3rd line settings

ARM 2

Current Therapies by Line for ER+/HER2- MBC — Wave 4



Note: Numbers <4% are not displayed
Question added in Wave 4; Arm 2

Base = Total Oncologists: W4 (n=100)

QA17a Please think about the post-menopausal ER+/HER2- MBC patients you saw in the past 3 months. For each line of therapy, what percent received each of the following therapies?





Afinitor ER+/HER2-Breast Cancer ATU – Wave 10

REVISED July 15, 2015




Conducted by: **Adelphi**
ADELPHI RESEARCH



Ibrance's impact is seen in 1st Line as 16% Share is identified for it, likely from tamoxifen and letrozole (monotherapy). Afinitor drops to low twenties in 2nd L and mid-teens in Third Line.

Current Therapies by Line for ER+/HER2-MBC

Weighted by Total Patient Volume



*Weighted by total ER+/HER2-patient volume; outliers removed
 Numbers <4% are not displayed; Faslodex + Arimidex added in W8
 Base = Total Oncologists: W5 (n=94); W6 (n=88); W7 (n=82); W8 (n=80); W9 (n=89)
 QA17a Please think about the post-menopausal ER+/HER2- MBC patients you saw in the past 3 months.
 For each line of therapy, what percent received each of the following therapies?

